Company intelligence / Profile preview

Unity Tool

South San Francisco, California, United Statesunityprecisionmfg.com ↗

Ownership: Private
Employees: ~16
Development stage: Commercial

Overview

UBX1325, the lead candidate targeting BCL-xL for age-related eye diseases such as diabetic macular edema and age-related macular degeneration, is currently in a Phase 2b trial ("ASPIRE") with topline results expected Q1/Q2 2025. The company has additional preclinical programs targeting ophthalmologic and neurology indications.

Therapeutic areas: OphthalmologyNeurology
Modalities: Small moleculeMonoclonal antibodyProtein
Industry: Biotech

Beyond the preview

Go deeper on Unity Tool.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unity Tool.

Explore the full profile